Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS1-1-01 in Moderate to Severe Depression
NCT07485595Phase 3Not yet recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JS1-1 in major depressive disorder (MDD), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
JS1-1
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07485595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07485595.